Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, LTD. on November 19, 2024. The Company is a Delaware corporation with its principal executive offices in Los Angeles, California. Its common stock (Ticker: KAPA) is registered on the NYSE American LLC.
Key Financial Metrics
This filing is a regulatory disclosure regarding a corporate event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The primary material event reported is the Company's approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Key details include:
- Trading Commencement: November 26, 2024, at 10:00 a.m. ET.
- Ticker Symbol: KAPA (remains unchanged).
- Strategic Objective: To access a global investor base outside the U.S., unlock liquidity, enhance price discovery, and globalize investment opportunities.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the anticipated benefits of the dual listing. Management cautions that actual results may differ materially due to known and unknown risks, uncertainties, and assumptions. The Company explicitly states it undertakes no obligation to update these forward-looking statements except as required by law. No specific financial guidance or operational outlook is provided in this report.
Investor Verification Checklist
- Verify the commencement of trading on the Upstream platform on November 26, 2024.
- Review the attached press release (Exhibit 99.1) for additional details on the dual listing agreement.
- Consult the Company's Form S-1 and periodic reports for comprehensive risk factors and financial data, as this 8-K does not contain financial metrics.
- Monitor liquidity and price discovery impacts post-listing as described in management's strategic goals.